Published in J Clin Invest on August 01, 1988
Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest (1989) 5.21
Plant defensins: novel antimicrobial peptides as components of the host defense system. Plant Physiol (1995) 3.03
Resistance to host antimicrobial peptides is necessary for Salmonella virulence. Proc Natl Acad Sci U S A (1992) 2.99
Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest (1989) 2.50
Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev (2010) 1.97
Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol (2013) 1.73
Antibiotic proteins of human neutrophils. J Clin Invest (1990) 1.67
Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med (1997) 1.60
The giant organelles in beige and Chediak-Higashi fibroblasts are derived from late endosomes and mature lysosomes. J Exp Med (1993) 1.50
Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med (1999) 1.44
The human cationic host defense peptide LL-37 mediates contrasting effects on apoptotic pathways in different primary cells of the innate immune system. J Leukoc Biol (2006) 1.25
Inactivation of the sapA to sapF locus of Erwinia chrysanthemi reveals common features in plant and animal bacterial pathogenesis. Plant Cell (1998) 1.17
In vitro sensitivity of oral, gram-negative, facultative bacteria to the bactericidal activity of human neutrophil defensins. Infect Immun (1990) 1.13
Infections in patients with inherited defects in phagocytic function. Clin Microbiol Rev (2003) 1.02
In vitro killing of oral Capnocytophaga by granule fractions of human neutrophils is associated with cathepsin G activity. J Clin Invest (1991) 1.01
Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. Am J Pathol (2008) 0.98
Elevated plasma interleukin-6 levels in trained male triathletes following an acute period of intense interval training. Eur J Appl Physiol (2006) 0.94
Susceptibility to infectious diseases based on antimicrobial peptide production. Infect Immun (2009) 0.94
Manual annotation and analysis of the defensin gene cluster in the C57BL/6J mouse reference genome. BMC Genomics (2009) 0.93
Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J (2009) 0.93
Differential killing of Actinobacillus actinomycetemcomitans and Capnocytophaga spp. by human neutrophil granule components. Infect Immun (1991) 0.84
Selective defect in myeloid cell lactoferrin gene expression in neutrophil specific granule deficiency. J Clin Invest (1989) 0.83
The PhoQ-activating potential of antimicrobial peptides contributes to antimicrobial efficacy and is predictive of the induction of bacterial resistance. Antimicrob Agents Chemother (2007) 0.80
Killing of staphylococci by θ-defensins involves membrane impairment and activation of autolytic enzymes. Antibiotics (Basel) (2014) 0.80
The antimicrobial propeptide hCAP-18 plasma levels in neutropenia of various aetiologies: a prospective study. Sci Rep (2015) 0.77
Approach to the child with recurrent infections. J Family Community Med (2009) 0.77
Human α-defensin expression is not dependent on CCAAT/enhancer binding protein-ε in a murine model. PLoS One (2014) 0.76
SMARCD2 subunit of SWI/SNF chromatin-remodeling complexes mediates granulopoiesis through a CEBPɛ dependent mechanism. Nat Genet (2017) 0.76
Congenital defects in neutrophil dynamics. J Immunol Res (2014) 0.76
Skin fibroblasts from individuals with Chediak-Higashi Syndrome (CHS) exhibit hyposensitive immunogenic response. Orphanet J Rare Dis (2014) 0.76
In vitro studies on the antimicrobial peptide human beta-defensin 9 (HBD9): signalling pathways and pathogen-related response (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2014) 0.75
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
Disk electrophoresis of basic proteins and peptides on polyacrylamide gels. Nature (1962) 20.19
Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest (1985) 8.63
ELECTRON MICROSCOPE STUDIES ON THE DEGRANULATION OF RABBIT PERITONEAL LEUKOCYTES DURING PHAGOCYTOSIS. J Exp Med (1964) 6.12
Biochemical and morphological characterization of azurophil and specific granules of human neutrophilic polymorphonuclear leukocytes. J Cell Biol (1974) 3.71
Abnormal bactericidal, metabolic, and lysosomal functions of Chediak-Higashi Syndrome leukocytes. J Clin Invest (1972) 3.69
The Chediak-Higashi syndrome: studies in four patients and a review of the literature. Medicine (Baltimore) (1972) 2.74
Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem (1979) 2.66
Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest (1986) 2.22
Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun (1987) 2.07
Bactericidal activity of specific and azurophil granules from human neutrophils: studies with outer-membrane mutants of Salmonella typhimurium LT-2. Infect Immun (1978) 2.04
In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood (1986) 2.01
Nonoxidative antimicrobial reactions of leukocytes. Contemp Top Immunobiol (1984) 1.97
Phagocytosis in chronic granulomatous disease and the Chediak-Higashi syndrome. N Engl J Med (1972) 1.96
Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Blood (1982) 1.62
Specific protease deficiency in polymorphonuclear leukocytes of Chédiak-Higashi syndrome and beige mice. J Exp Med (1978) 1.60
Defensin-rich dense granules of human neutrophils. Blood (1987) 1.59
Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med (1981) 1.58
Antimicrobial activity of phagocyte granule proteins. Semin Respir Infect (1986) 1.49
An anomaly of neutrophil morphology with impaired function. N Engl J Med (1974) 1.23
Lysosomal enzymes in normal and Chediak-Higashi blood leukocytes. J Lab Clin Med (1975) 1.20
Cytotoxicity for tumor cells of cationic proteins from human neutrophil granules. J Cell Biol (1976) 1.18
Lactoferrin deficiency associated with altered granulocyte function. N Engl J Med (1982) 1.17
Lysosomal elastase and cathepsin G in beige mice. Neutrophils of beige (Chediak-Higashi) mice selectively lack lysosomal elastase and cathepsin G. J Exp Med (1986) 1.14
Defective bactericidal activity and absence of specific granules in neutrophils from a patient with recurrent bacterial infections. J Clin Immunol (1984) 1.03
Neutrophil specific granule deficiency. Annu Rev Med (1985) 0.97
Phagocyte defects. Clin Immunol Immunopathol (1986) 0.93
Anomalous neutrophil granule distribution in a patient with lactoferrin deficiency: pertinence to the respiratory burst. Am J Hematol (1985) 0.89
The Chediak-Higashi syndrome: quantitation of a deficiency in maximal bactericidal capacity. Am J Pathol (1979) 0.87
Abnormal distribution of complex carbohydrates in neutrophils of a patient with lactoferrin deficiency. Blood (1983) 0.84
Chédiak-Higashi syndrome neutrophils are characterized by the absence of both normal azurophilic granules. Am J Pathol (1986) 0.80
Interaction of Candida albicans with human leukocytes and serum. J Bacteriol (1969) 9.19
Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest (1985) 8.63
Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest (1969) 7.61
Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) (2000) 7.17
Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med (1999) 5.82
Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes. Infect Immun (1984) 5.30
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol (1973) 4.61
Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) (2000) 4.45
The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med (1995) 4.25
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
The regulatory role of divalent cations in human granulocyte chemotaxis. Evidence for an association between calcium exchanges and microtubule assembly. J Cell Biol (1974) 4.10
Phagocytosis by human monocytes. Blood (1968) 3.96
Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A (1990) 3.90
Primary structures of three human neutrophil defensins. J Clin Invest (1985) 3.70
Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem (1985) 3.58
Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood (2000) 3.45
Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother (1998) 3.45
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med (1997) 3.40
Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett (1996) 3.39
Structural analysis of human neutrophil migration. Centriole, microtubule, and microfilament orientation and function during chemotaxis. J Cell Biol (1977) 3.33
Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett (1993) 3.30
Current concepts: immunology. Neutrophils in human diseases. N Engl J Med (1987) 3.29
Antifungal effects of peroxidase systems. J Bacteriol (1969) 3.24
Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science (1990) 3.15
Microbicidal cationic proteins in rabbit alveolar macrophages: a potential host defense mechanism. Infect Immun (1980) 3.13
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci U S A (1998) 3.02
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages. J Biol Chem (1983) 3.00
Direct inactivation of viruses by human granulocyte defensins. J Virol (1986) 3.00
Defensins. Eur J Haematol (1990) 2.88
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med (1996) 2.86
The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood (1976) 2.76
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
H2O2 release from human granulocytes during phagocytosis. Relationship to superoxide anion formation and cellular catabolism of H2O2: studies with normal and cytochalasin B-treated cells. J Clin Invest (1977) 2.71
Nonoxidative fungicidal mechanisms of mammalian granulocytes: demonstration of components with candidacidal activity in human, rabbit, and guinea pig leukocytes. Infect Immun (1975) 2.68
Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet (1999) 2.63
NADPH oxidase deficiency in X-linked chronic granulomatous disease. J Clin Invest (1975) 2.62
Role of secretory events in modulating human neutrophil chemotaxis. J Clin Invest (1978) 2.59
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Defensins. Curr Opin Immunol (1994) 2.55
Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin Infect Dis (1998) 2.53
Defensins. Pharmacol Ther (1995) 2.52
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
The selective eosinophil chemotactic activity of histamine. J Exp Med (1975) 2.45
Crystallization of antimicrobial pores in membranes: magainin and protegrin. Biophys J (2000) 2.41
Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest (1975) 2.40
Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science (1989) 2.39
Cryptdins: antimicrobial defensins of the murine small intestine. Infect Immun (1992) 2.39
Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin, and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol (1986) 2.36
Neutrophil action dysfunction and abnormal neutrophil behavior. N Engl J Med (1974) 2.35
Cyclic 3',5'-adenosine monophosphate in the human lukocyte: synthesis, degradation, andeffects n neutrophil candidacidal activity. J Clin Invest (1971) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
Antibacterial activity of microbicidal cationic proteins 1 and 2, natural peptide antibiotics of rabbit lung macrophages. Infect Immun (1983) 2.33
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Direct inactivation of viruses by MCP-1 and MCP-2, natural peptide antibiotics from rabbit leukocytes. J Virol (1985) 2.31
The fungicidal mechanisms of human monocytes. I. Evidence for myeloperoxidase-linked and myeloperoxidase-independent candidacidal mechanisms. J Clin Invest (1975) 2.26
Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med (2000) 2.26
Functional aspects of a second mechanism of candidacidal activity by human neutrophils. J Clin Invest (1972) 2.25
Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol (1995) 2.25
Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun (2000) 2.24
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci U S A (2000) 2.20
Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol (1979) 2.20
Susceptibility of Chlamydia trachomatis to protegrins and defensins. Infect Immun (1996) 2.16
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet (1999) 2.13
Assessment of chlorination by human neutrophils. Nature (1983) 2.12
Autooxidation as a basis for altered function by polymorphonuclear leukocytes. Blood (1977) 2.10
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med (1994) 2.07
Activity of rabbit leukocyte peptides against Candida albicans. Infect Immun (1985) 2.05
Men account for a scant 3% of all nurses. J Nurse Midwifery (1992) 2.05
Granulocyte function in the Chediak-Higashi syndrome of mice. Blood (1974) 2.04
Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) (1998) 2.03
Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem (1993) 2.02
Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci (1979) 2.02
Mouse neutrophils lack defensins. Infect Immun (1992) 2.01
In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood (1986) 2.01
Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science (1988) 2.00
Thrombospondin binds to Staphylococcus aureus and promotes staphylococcal adherence to surfaces. Infect Immun (1991) 1.99
Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol (2001) 1.97
Use of lipophilic probes of membrane potential to assess human neutrophil activation. Abnormality in chronic granulomatous disease. J Clin Invest (1980) 1.97
Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis (1978) 1.97
Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis (2000) 1.96
IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol (1990) 1.94
Antimicrobial peptides of vertebrates. Curr Opin Immunol (1998) 1.94
Serum lipids in infection. N Engl J Med (1969) 1.93
Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med (1989) 1.93
Correlation of binding of rabbit granulocyte peptides to Candida albicans with candidacidal activity. Infect Immun (1985) 1.89
Neutrophil defensins: purification, characterization, and antimicrobial testing. Methods Enzymol (1994) 1.88
Solution structure of protegrin-1, a broad-spectrum antimicrobial peptide from porcine leukocytes. Chem Biol (1996) 1.87
Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest (1979) 1.85
Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis (1992) 1.84
In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis (1986) 1.84
Separation and functional characterization of human neutrophil subpopulations. Blood (1978) 1.80